Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. (Q36856371)
Jump to navigation
Jump to search
scientific article published on 29 September 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. |
scientific article published on 29 September 2011 |
Statements
Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial (English)
1 reference
S L Samson
P Sathyanarayana
M Jogi
E V Gonzalez
A Gutierrez
R Krishnamurthy
L Chan
29 September 2011